We are live on ! Find out more
OKYO

OKYO Pharma

12 hedge funds and large institutions have $10.3M invested in OKYO Pharma in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

796% more capital invested

Capital invested by funds: $1.15M → $10.3M (+$9.14M)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

20% more funds holding

Funds holding: 1012 (+2)

13.99% more ownership

Funds ownership: 1.77%15.76% (+14%)

Holders
12
Holders Change
+2
Holders Change %
+20%
% of All Funds
0.15%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
2
Reduced
1
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
WP
1
Woodline Partners
California
$5.88M +$7.09M +3,652,190 New
MS
2
Maven Securities
Jersey
$1.89M +$2.28M +1,175,535 New
SCM
3
Stonepine Capital Management
Oregon
$1.37M +$1.65M +850,000 New
Balyasny Asset Management
4
Balyasny Asset Management
Illinois
$942K +$1.14M +584,796 New
UBS Group
5
UBS Group
Switzerland
$96.2K +$112K +57,588 +2,651%
XT
6
XTX Topco
Cayman Islands
$60.6K +$38.9K +20,040 +114%
Cerity Partners
7
Cerity Partners
New York
$20.6K
Geode Capital Management
8
Geode Capital Management
Massachusetts
$19.5K
DIG
9
Dauntless Investment Group
New Hampshire
$6.15K -$908K -467,704 -99%
EI
10
EFG International
$1.49K
Osaic Holdings
11
Osaic Holdings
Arizona
$244
Morgan Stanley
12
Morgan Stanley
New York
$16
Renaissance Technologies
13
Renaissance Technologies
New York
-$286K -138,000 Closed
Wealth Enhancement Advisory Services
14
Wealth Enhancement Advisory Services
Minnesota
-$21.2K -10,000 Closed

OKYO Hedge Fund Activity: Q1 2026 in Review

12 of the 8,143 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q1 2026, worth a combined $10.3M — up 796% from $1.15M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new OKYO positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Woodline Partners, opening a new position worth an estimated $7.09M. The largest seller was Dauntless Investment Group, cutting an estimated $908K.

  • 12 institutional investors held OKYO Pharma (OKYO) as of Q1 2026, up from 10 in Q4 2025.
  • Funds reported $10.3M of OKYO Pharma stock for Q1 2026, up 796% quarter-over-quarter.
  • 4 funds opened new OKYO Pharma positions in Q1 2026 and 2 closed out, a net change of +2 holders.
  • The largest OKYO Pharma buyer in Q1 2026 was Woodline Partners, an estimated $7.09M added.
  • The largest OKYO Pharma seller in Q1 2026 was Dauntless Investment Group, an estimated $908K sold.

Based on aggregated 13F filings for Q1 2026.